Press Releases Detail:
Avitar, Inc. Featured On Ceocast.Com Investor Program
Avitar’s CEO Peter P. Phildius interviewed by CEOcast.com
March 08, 2001
CANTON, MA, March 8, 2001 – Avitar Inc. (AMEX:AVR) announced today that the company will be featured on CEOcast.com, a financial website forum. Peter P. Phildius, Avitar’s Chairman and Chief Executive Officer, was interviewed by CEOcast.com on January 23, 2001 in an effort by CEOcast to highlight companies with growth potential in the rapidly growing alternative sample substance abuse testing market.
The interview of Avitar’s Chairman and CEO was conducted by Michael Wachs, CEOcast’s biotech analyst and can be accessed online for the next 90 days at. Mr. Phildius discussed advances in the company’s drugs of abuse products including ORALscreen™, the world’s first rapid onsite drugs of abuse test utilizing oral fluid. He also expanded on the potential for rapid growth of the alternative sample testing market and the competitive advantage that Avitar has in developing new technologies for clinical diagnostic tests using oral fluid.
"CEOcast has an impressive audience of institutional investors, and we are excited to be featured on their website. As a leader in the rapidly changing drugs of abuse testing market, it is important to spread our message into the investment community as efficiently as possible," said Peter P. Phildius, Chairman and CEO. "We believe that the institutional market will be very interested in our story because of Avitar’s high growth potential for alternative sample diagnostics in the rapidly growing $20 billion diagnostics market," Phildius added.
CEOcast, Inc. is a leading source of original and syndicated interviews with CEO’s at news making companies. CEOcast’s information is made available to buy side analysts and portfolio managers at over 3,600 institutions, investment research professionals representing over 600 institutions, and close to 300,000 registered biotechnology and pharmaceutical investors. It’s programming is also distributed to online investors at over 700 financial web sites. CEOcast assesses a fee of $7,500 for company features.
Avitar, Inc. (AMEX: AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The company markets a unique portfolio of substance abuse testing products and services that includes ORALscreenTM, the world’s first rapid point-of-collection oral fluid test for drugs of abuse, ORALadvantage™, the first comprehensive substance abuse program featuring Avitar’s oral fluid-based products, HAIRscreenTM, a laboratory-based test for detecting long term drug abuse using hair, and several other specialized tests for drugs of abuse. ORALscreen is a cost-effective drugs-of-abuse test with potential net cost savings of more than $100.00 per sample tested. Additional products include an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices.
For more information, see Avitar’s website at avitarinc.com.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
# # #